VU0469650（Cat No.:I011181）is a selective small molecule inhibitor that targets the protein GPR40 (G-protein coupled receptor 40), also known as FFAR1. GPR40 plays a crucial role in regulating insulin secretion and glucose homeostasis by responding to free fatty acids. By modulating GPR40 activity, VU0469650 enhances glucose-dependent insulin release, making it a potential therapeutic for type 2 diabetes and other metabolic disorders. Preclinical studies suggest that VU0469650 may help improve blood sugar control by promoting insulin secretion in response to nutrient signals, offering a promising approach for diabetes treatment.